(Hypertension. 2000;35:150.)
© 2000 American Heart Association, Inc.
Arthur C. Corcoran Lecture |
Implications of Species Difference for Clinical Investigation
Studies on the Renin-Angiotensin System
From the Departments of Radiology and Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
Abstract—The justification for clinical investigation has its roots in the fact that physiological mechanisms and disease pathogenesis in animal models replicate mechanisms and pathogenesis in humans only in part. In the case of the renin-angiotensin system, there is species variation in the anatomic distribution of the renin-angiotensin system, in the active site of the renin enzyme, and in the structure of angiotensin and the AT1 receptor. The conversion of angiotensin I (Ang I) to angiotensin II (Ang II) may prove to be the most important aspect of species variation. In plasma, all the conversion occurs through a single enzyme, angiotensin-converting enzyme (ACE), and species variation in structure and function have not been reported. Non–ACE-dependent pathways, which occur only at the tissue level, show unambiguous, striking species variation. Specifically, chymase, the most important enzyme responsible for non-ACE conversion of Ang I to Ang II, shows striking species variation. In humans and a number of species, including the hamster, quantitatively important chymase-independent Ang II formation from Ang I occurs in the heart, arteries, and kidney. In rats and rabbits, on the other hand, chymase differs, is not active in the conversion of Ang I to Ang II, and indeed is involved in Ang II degradation. Consequently, one would anticipate that blockade of the system at the ACE step would be equivalent to that at the Ang II receptor in the rat. This has been widely reported. In humans, on the other hand, one would anticipate that the AT1 receptor blockers will be more effective than ACE inhibitors. Again, preliminary evidence favors this possibility. The implications for therapeutics are clear.
Key Words: angiotensin I • angiotensin II • angiotensin-converting enzyme • human • rats • rabbits • hamsters
This article has been cited by other articles:
 |
|
 |
|
  Y. Ochiai, Y.-Q. Liang, M. Serizawa, and N. Kato Dynamic changes of the renin-angiotensin and associated systems in the rat after pharmacological and dietary interventions in vivo Physiol Genomics, November 12, 2008; 35(3): 330 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Terada, H. Kuwana, T. Kobayashi, T. Okado, N. Suzuki, T. Yoshimoto, Y. Hirata, and S. Sasaki Aldosterone-Stimulated SGK1 Activity Mediates Profibrotic Signaling in the Mesangium J. Am. Soc. Nephrol., February 1, 2008; 19(2): 298 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Palaniyandi, Y. Nagai, K. Watanabe, M. Ma, P. T. Veeraveedu, P. Prakash, F. A. Kamal, Y. Abe, K. Yamaguchi, H. Tachikawa, et al. Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats Experimental Biology and Medicine, October 1, 2007; 232(9): 1213 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Mitchell, J. M. O. Arnold, M. E. Dunlap, T. X. O'Brien, G. Marchiori, E. Warner, C. B. Granger, S. S. Desai, and M. A. Pfeffer Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM Program Eur J Heart Fail, March 1, 2006; 8(2): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Terada, T. Kobayashi, H. Kuwana, H. Tanaka, S. Inoshita, M. Kuwahara, and S. Sasaki Aldosterone Stimulates Proliferation of Mesangial Cells by Activating Mitogen-Activated Protein Kinase 1/2, Cyclin D1, and Cyclin A J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2296 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Seeliger, J. L. Andersen, P. Bie, and H. W. Reinhardt Elevated renal perfusion pressure does not contribute to natriuresis induced by isotonic saline infusion in freely moving dogs J. Physiol., September 15, 2004; 559(3): 939 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ritz Chymase: A Potential Culprit in Diabetic Nephropathy? J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1952 - 1954. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marchetti, C. M. B. Helou, C. Chollet, R. Rajerison, and F. Alhenc-Gelas Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: ACE and non-ACE mediated effect of angiotensin I on intracellular calcium mobilization in rat glomerular arterioles Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1933 - H1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koppel, M. Christ, B. A. Yard, P. C. Bar, F. J. van der Woude, and M. Wehling Nongenomic Effects of Aldosterone on Human Renal Cells J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1297 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Egleton, S. A. Mitchell, J. D. Huber, M. M. Palian, R. Polt, and T. P. Davis Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 967 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz and G. Heusch Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S136 - S140. [PDF]
|
|
|
|
|
|
M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]
|
|
|
|
|
|
M C. Lansang and N. K Hollenberg ACE inhibition and the kidney: species variation in the mechanisms responsible for the renal haemodynamic response Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 119 - 124. [PDF]
|
|